Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix

Canadian Journal of Surgery

Volumn 52, Issue 2, 2009, Pages 135-141

  Sideris, Lucas ^a   Mitchell, Andrew ^a   Drolet, Pierre ^a   Leblanc, Guy ^a   Ledere, Yves E ^a   Dubé, Pierre ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PLATINUM COMPLEX;

ADENOCARCINOMA, MUCINOUS; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANALOGS AND DERIVATIVES; APPENDIX TUMOR; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INFUSION; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; SECONDARY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; APPENDICEAL NEOPLASMS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUOROURACIL; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 67249086382     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. 1. Bradley RF, Stewart JH IV, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551-559 (Pubitemid 44265007)
2. 2. van Ruth S, Acherman YI, van de Vijver MJ, et al. Pseudomyxoma peritonei: a review of 62 cases. Eur J Surg Oncol 2003;29:682-688 (Pubitemid 37236291)
3. 3. Sherer DM, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature. Gynecol Obstet Invest 2001;51:73-80. (Pubitemid 32172914)
4. Sugarbaker PH, Shmookler B, Ronnett BM, et al. Pseudomyxoma peritonei. Br J Surg 1999;86:842.
5. Elias D, Sabourin JC. [Pseudomyxoma peritonei, a review] [article in French], J Chir (Paris) 1999;136:341-347
6. 6. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. Dis Colon Rectum 1987;30:772-779 (Pubitemid 17168045)
7. 7. Elias D, Dubé P, Blot F, et al. Peritoneal carcinomatosis treatment with curative intent: die Institut Gustave-Roussy experience. Eur J Surg Oncol 1997;23:317-321 (Pubitemid 27423503)
8. 8. Sugarbaker PH. New standard of care for appendiceal epithelial neo- plasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69-76. (Pubitemid 43025395)
9. Elias D, Laurent S, Antoun S, et al. [Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy] [article in French]. Gastroenterol Clin Biol 2003;27:407-412
10. 10.DeracoM,GronchiA,MazzaferroV,etal. Feasibilityofperitonectomyassociatedwithintraperitonealhyperthe rmicperfusioninpatientswithpseudomyxomaperitonei.Tumori2002;88: 370-375(Pubitemid35356102)
11. Ronnett BM, Shmookler BM, Sugarbaker PH, et al. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197-226.
12. Sugarbaker PH. Pseudomyxoma peritonei. Cancer Treat Res 1996;81: 105-119
13. 13. Los G, Ruevekamp M, Bosnie N, et al. Intraperitoneal tumor growth and chemodierapy in a rat model. Eur J Cancer Clin Oncol 1989; 25:1857-1866 (Pubitemid 20084188)
14. 14.LosG,MutsaersPH,vanderVijghWJ,etal. Directdiffusionofcisdiamminedichloroplatinum(II) inintraperitonealrattumorsafterintraperitonealchemotherapy: acomparisonwithsystemicchemotherapy.CancerRes1989;49:3380-84(Pubitemid19162154)
15. 15. Zoetmulder FA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer 1996;32A: 1727-1733 (Pubitemid 26306884)
16. 16. Elias D, Raynard B, Bonnay M, et al. Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies. Eur J Surg Oncol 2006; 32:607-613 (Pubitemid 44063994)
17. 17. Elias D, Matsuhisa T, Sideris L, et al. Heated intraoperative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004; 15:1558-1565 (Pubitemid 39409748)
18. 18. Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002; 13:267-272 (Pubitemid 34704979)
19. Elias D, Antoun S, Goharin A, et al. Research on die best chemohyperdiermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig 2000; 1:431-439
20. 20. Ceelen WP, Hesse U, de Hemptinne B, et al. Hyperthermic intraperitoneal chemoperfusion in die treatment of locally advanced intraabdominal cancer. Br J Surg 2000;87:1006-1015 (Pubitemid 30496848)
21. 21.RiethroekRC,vandeVaartPJ,HavemanJ,etal. Hyperdiermiaenhancesdiecytotoxicityandplatinum- DNAadductformationoflobaplatinandoxaliplatininculturedSVV1573cells. JCancerResClinOncol1997;123:6-12.(Pubitemid26414189)
22. 22.VaronaJF,GuerraJM,SalamancaJ,etal.Pseudomyxomaperitonei: aclinicopadiologicanalysisandfollow-upof21patients.Hepatogastroenterology2005; 52:812-816(Pubitemid40834610)
23. 23. Sugarbaker PH, Stuart OA, Yoo D. Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy. J Oncol Pharm Pract 2005;11:111-119 (Pubitemid 41488928)
24. 24. Verwaal VJ, Zoetmulder FA. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2004;30:280-285 (Pubitemid 38425645)
25. Iversen LH, Rasmussen PC, Wara P, et al. [Pseudomyxoma peritonei] [article in Danish], Ugeskr Laeger 2004;166:2979-2981
26. 26. Elias D, Pocard M, Sideris L, et al. Preliminary results of intraperitoneal chemohyperdiermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:455-456 (Pubitemid 38491115)
27. 27. Widcamp AJ, de Bree E, Kaag MM, et al. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001;88: 458-463 (Pubitemid 32238713)
28. Zoetmulder FA, van der Vange N, Witkamp AJ, et al. [Hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from die Netherlands Cancer Institute] [Article in Dutch]. Ned Tijdschr Geneeskd 1999;143:1863-1868
29. 29.SugarbakerPH,ChangD. Resultsoftreatmentof385patientswithperitoneal surface spreadofappendicealmalignancy.AnnSurgOncol1999;6:727-731(Pubitemid30013648)
30. 30.SugarbakerPH.Managementofperitoneal-surfacemalignancy: thesurgeon'srole.LangenbecksArchSurg1999;384:576-587(Pubitemid30020346)
31. 31. Sugarbaker PH. Intraperitoneal chemodierapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and Sarcomatosis. Semin Surg Oncol 1998;14:254-261 (Pubitemid 28146518)
32. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29-42.
33. 33. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis dian patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91. (Pubitemid 32623044)
34. 34.SugarbakerPH.Pseudomyxomaperitonei. Acancerwhosebiologyischaracterizedbyaredistributionphenomenon.AnnSurg1994;219: 109-111(Pubitemid24064066)
35. 35.PraysonRA,HartWR,PetrasRE.Pseudomyxomaperitonei. Aclinicopadiologicstudyof19cases with emphasisonsiteoforiginandnatureofassociatedovariantumors.AmJSurgPathol1994;18: 591-603.(Pubitemid24150808)
36. 36.PanH,McGaryC,LaVorgnaKA,etal.Pseudomyxomaperitonei. Gastr-oenteralogist1998;6:147-150(Pubitemid28285389)
37. 37. Jivan S, Bahal V. Pseudomyxoma peritonei. Postgi-ad Med J 2002;78: 170-172 (Pubitemid 34229627)
38. Jähne J. Extensive surgical cytoreduction and intraoperative hyper- thermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei(Br J Surg 2001; 88:458-63).
39. Br J Surg 200l;88:1130.
40. 39. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol 2005;12:291-311. (Pubitemid 44357148)
41. 40.JacqueminG,LalouxP.Pseudomyxomaperitonei: reviewonaclusterofperitonealmucinousdiseases.ActaChirBelg2005;105: 127-133(Pubitemid40694508)
42. Galani E, Marx GM, Steer CB, et al. Pseudomyxoma peritonei: the 'controversial' disease. Int J Gynecol Cancer 2003;13:413-418
43. Vana J, Adamicova K, Johanes R, et al. [Appendiceal mucocele causing pseudomyxoma peritonei] [Article in German], Zentralbl Chir 2005;130:177-180
44. 43. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperdiermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001;37:979-984 (Pubitemid 32397682)
45. 44. El-Malt M, Ceelen W, van den Broecke C, et al. Healing of experimental colonic anastomoses: effects of combined preoperative highdose radiotherapy and intraperitoneal 5-fluorouracil. Int J Cancer 2001;96:297-304. (Pubitemid 32946475)
46. 45.ReddyGK,GibsonAD,PriceN. EvolutionofFOLFOXregimensindietreatmentofadvancedcolorectalcancer. ClinColorectalCancer2005;4:296-299(Pubitemid40309374)
47. 46. Park SH, Sung JY, Han SH, et al. Oxaliplatin, folinic acid and 5fluorouracil (FOLFOX-4) combination chemodierapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. Jpn J Clin Oncol 2005;35:531-535 (Pubitemid 41573943)
48. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinar)' Research Group(GERCOR). Ann Oncol 2000;11:1477-1483
49. Mabro M, Artru P, André T, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients, fir 7 Cancer- 2006; 94:1287-1292
50. Hebbar M, Tournigand C, Lledo G, et al. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients widi metastatic colorectal cancer (FIREFOX study). Cancer Invest 2006;24:154-159
51. de Gramont A, Tournigand C, Louvet C, et al. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD] [article in French], Rev Med Interne 1997;18:769-775
52. Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005;241:300-308